MedTrace Logo

A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.

NCT00160433 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2008-05-29

No results posted yet for this study

Summary

The objective of this study is to determine the safety and efficacy of 3 asoprisnil doses (0.5 mg, 1.5 mg, and 5.0 mg) for 12 weeks in women with endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

Asoprisnil

0.5 mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

1.5 mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

5.0 mg Tablet, oral Daily for 12 weeks

DRUG

Placebo

Tablet, oral Daily for 12 weeks

Sponsors & Collaborators

  • Jenapharm GmbH & Co. KG

    collaborator UNKNOWN

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Medical Director · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2003-06-30
Completion
2003-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160433 on ClinicalTrials.gov